Cancilico, a Dresden-based medtech startup specializing in AI-powered oncology diagnostics, has announced the closing of a €2.5 million seed funding round. ## AI-Enhanced Oncology Diagnostics Founded in 2023 as a spin-off of the EKFZ for Digital Health at TUD Dresden, University of Technology, and University Hospital Dresden, Cancilico focuses on developing AI-driven diagnostic solutions for haematology. The goal is to automate and improve the accuracy of blood and bone marrow analysis. MyeloAID, the company's flagship product, uses advanced AI algorithms to analyze bone marrow samples with speed and precision. The technology can be implemented on any standard imaging microscope or scanner, allowing laboratories to upgrade their diagnostic capabilities without replacing existing hardware infrastructure. ## Investors and Future Prospects The investment was led by a consortium including High-Tech Gründerfonds (HTGF), TGFS - Technologiegründerfonds Sachsen, GEDAD GmbH, and ROI Verwaltungsgesellschaft. The funds will be used to accelerate the commercialization of the MyeloAID software and to obtain the necessary regulatory certifications (FDA and CE-IVDR). Markus Badstübner, CEO and co-founder of Cancilico, emphasized how the investment will make specialist diagnoses more accessible, improving patient care without requiring large capital expenditures. ## The Problem of Hematologist Shortage The global shortage of hematologists, coupled with the increasing complexity of diagnostic cases, represents a significant challenge for the healthcare sector. Solutions like MyeloAID, which leverage artificial intelligence to automate and improve the accuracy of analyses, can help overcome this criticality, allowing physicians to focus on more complex cases and provide more timely and effective care.